Avaleht/Aktsiad/GMAB

GMAB

USD

Genmab A/S ADS

$28.975+0.435 (1.524%)

Reaalajas hind

Healthcare

Biotehnoloogia

Taani

Hinnagraafik

Loading Chart...

Põhinäitajad

Turunäitajad

Ettevõtte fundamentaalnäitajad

Kauplemisstatistika

Turunäitajad

Avatud

$28.540

Kõrge

$29.390

Madal

$28.510

Maht

2.92M

Ettevõtte fundamentaalnäitajad

Turukapitalisatsioon

17.8B

Tööstusharu

Biotehnoloogia

Riik

Denmark

Kauplemisstatistika

Keskmine maht

2.00M

Börs

NMS

Valuuta

USD

52 nädala vahemik

Madal $17.235Praegune $28.975Kõrge $33.65

Seotud uudised

3. nov 2025 · 14:05

BusinessWire

Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual Meeting

More than 20 abstracts, including seven oral presentations, highlight advancements from the epcoritamab development program supporting the expanded clinical profile and potential of epcoritamab for a broader range of

Vaata rohkem

Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual Meeting

15. okt 2025 · 10:29

Analyst Upgrades

HC Wainwright & Co. Reiterates Buy on Genmab, Maintains $40 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Genmab with a Buy and maintains $40 price target.

Vaata rohkem

HC Wainwright & Co. Reiterates Buy on Genmab, Maintains $40 Price Target

14. okt 2025 · 10:23

GlobeNewswire

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2025

Company Announcement Net sales of DARZALEX® in the third quarter of 2025 totaled USD 3,672 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech,

Vaata rohkem